Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 13/20 | 0.44 |
| ▸ | CD74 | P04233 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400183 | 0.87 | ADORA2A (0.52) | ADORA2AADORA2BCD74MIFGPR55 | |
| SCHEMBL20436613 | 0.87 | ADORA2A (0.47) | ADORA2AADORA2BCD74MIFGPR55 | |
| SCHEMBL29653564 | 0.85 | ADORA2A (0.55) | ADORA2AADORA2BCD74MIFGPR55 | |
| SCHEMBL20416884 | 0.85 | ADORA2A (0.55) | ADORA2AADORA2BCD74MIFGPR55 | |
| SCHEMBL20400756 | 0.85 | ADORA2A (0.48) | ADORA2AADORA2BCD74MIFGPR55 | |
| SCHEMBL27029403 | 0.84 | ADORA2A (0.47) | ADORA2AADORA2BCD74MIFGPR55 | |
| SCHEMBL20436604 | 0.84 | ADORA2A (0.51) | ADORA2AADORA2BKLKB1CYP19A1 | |
| SCHEMBL20436595 | 0.84 | ADORA2A (0.62) | ADORA2AADORA2BCYP19A1 | |
| SCHEMBL20436606 | 0.82 | ADORA2A (0.47) | ADORA2AADORA2BKLKB1CYP19A1 | |
| SCHEMBL20436596 | 0.82 | ADORA2A (0.54) | ADORA2AADORA2BKLKB1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |